Phaseline

Companies › Diamyd Medical

Diamyd Medical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Diamyd
GAD65 antigen therapy
GAD2Phase 2Diabetes Mellitus, Type 1Mar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05683990DiamydPhase 2Diabetes Mellitus, Type 1Metabolic and endocrineMar 2028

Targets

GAD2 (1)

Companies with the same targets

–

Companies built like this

Zhuhai Rui-Inno Pharmaceutical Technology Tonghua Dongbao Pharmaceutical Portal Therapeutics Op-T Housey Healthcare ULC

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.